Performance of the Bladder EpiCheck™ Methylation Test for Patients Under Surveillance for Non–muscle-invasive Bladder Cancer: Results of a Multicenter,

Slides:

Advertisements

Similar presentations

Volume 70, Issue 2, Pages (August 2016)

Advertisements

Volume 68, Issue 4, Pages (October 2015)

Volume 63, Issue 3, Pages (March 2013)

Volume 71, Issue 6, Pages (June 2017)

Volume 64, Issue 3, Pages (September 2013)

Volume 70, Issue 6, Pages (December 2016)

Volume 55, Issue 3, Pages (March 2009)

Managing Cancer Pain: Basic Principles and Invasive Treatments

Volume 57, Issue 1, Pages (January 2010)

Volume 59, Issue 3, Pages (March 2011)

Volume 65, Issue 4, Pages (April 2014)

Maintenance Bacillus Calmette-Guérin: The Standard of Care for the Prophylaxis and Management of Intermediate- and High-Risk Non–Muscle-Invasive Bladder.

Volume 73, Issue 2, Pages (February 2018)

Systemic Inflammatory Markers and Oncologic Outcomes in Patients with High-risk Non–muscle-invasive Urothelial Bladder Cancer Francesco Cantiello, Giorgio.

European Urology Oncology

Yair Lotan, Peter C. Black, Laura Caba, Sam S. Chang, Michael S

Volume 66, Issue 6, Pages (December 2014)

Volume 71, Issue 6, Pages e171-e172 (June 2017)

Ashish M. Kamat, Sima Porten European Urology

European Urology Oncology

Bladder Cancer: A Major Public Health Issue

Volume 71, Issue 6, Pages (June 2017)

What is New in Bladder Cancer Diagnosis and Management?

New Trends in Bladder Cancer Management

Clinical Practice Recommendations for the Management of Non–Muscle Invasive Bladder Cancer Donald Lamm, Marc Colombel, Raj Persad, Mark Soloway, Andreas.

The Importance of Transurethral Resection in Managing Patients With Urothelial Cancer in the Bladder: Proposal for a Transurethral Resection of Bladder.

Adjuvant Antiangiogenic Agents in Post-nephrectomy Renal Cell Carcinoma: A Systematic Review and Meta-analysis Mohamad B. Sonbol, Belal Firwana, Talal.

Volume 68, Issue 3, Pages (September 2015)

P.M.J. Moonen, L.A.L.M. Kiemeney, J.A. Witjes European Urology

Volume 63, Issue 5, Pages (May 2013)

Volume 69, Issue 3, Pages (March 2016)

Volume 64, Issue 3, Pages (September 2013)

Volume 55, Issue 3, Pages (March 2009)

Volume 66, Issue 6, Pages (December 2014)

Clinical Practice Recommendations for the Management of Non–Muscle Invasive Bladder Cancer Donald Lamm, Marc Colombel, Raj Persad, Mark Soloway, Andreas.

Active Surveillance for Prostate Cancer in a Real-life Cohort: Comparing Outcomes for PRIAS-eligible and PRIAS-ineligible Patients Timo F.W. Soeterik,

Stephen B. Williams, Ashish M

Long-term Cancer-specific Survival in Patients with High-risk, Non–muscle-invasive Bladder Cancer and Tumour Progression: A Systematic Review Sven van.

Volume 70, Issue 2, Pages (August 2016)

Volume 70, Issue 6, Pages (December 2016)

Volume 68, Issue 4, Pages (October 2015)

Volume 50, Issue 3, Pages (September 2006)

Selma Masic, Janet E. Cowan, Samuel L. Washington, Hao G

Volume 153, Issue 3, Pages e16-e17 (September 2017)

Development and External Validation of Nomograms To Predict Adverse Pathological Characteristics After Robotic Prostatectomy: Results of a Prospective,

European Urology Oncology

Single-dose antibiotic prophylaxis for urinary catheter removal does not reduce the risk of urinary tract infection in surgical patients: a randomized.

Effectiveness of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer in the Current Real World Setting in the USA Nawar Hanna, Quoc-Dien Trinh,

Optimizing the Timing of Salvage Postprostatectomy Radiotherapy and the Use of Concurrent Hormonal Therapy for Prostate Cancer Amar U. Kishan, Rahul.

Volume 53, Issue 5, Pages (May 2008)

Bladder Cancer: Highlights from 2006

Psychotherapeutic Interventions Targeting Prostate Cancer Patients: A Systematic Review of the Literature Liliana Vartolomei, Shahrokh F. Shariat, Mihai.

Cumulative Cancer Locations is a Novel Metric for Predicting Active Surveillance Outcomes: A Multicenter Study Andrew M. Erickson, Stefano Luzzago, Axel.

A Multidisciplinary Team Approach for the Optimal Clinical Management of Metastatic Hormone-Refractory Prostate Cancer—Case Study John Fitzpatrick European.

The Cost to Medicare of Bladder Cancer Care

Economic Burden of Bladder Cancer Across the European Union

Volume 52, Issue 4, Pages (October 2007)

Clinical Practice Recommendations for the Prevention and Management of Intravesical Therapy–Associated Adverse Events J. Alfred Witjes, Joan Palou, Mark.

European Urology Oncology

European Urology Oncology

Prognostic Factors in Non–Muscle-Invasive Bladder Tumors

Early Single-Instillation Chemotherapy Has No Real Benefit and Should Be Abandoned in Non–Muscle-Invasive Bladder Cancer Sten Holmäng European Urology.

Clinical Management of Patients Receiving Tyrosine Kinase Inhibitors for Advanced Renal Cell Carcinoma Jan Roigas European Urology Supplements Volume.

Pain Response Rates After Conventional Radiation Therapy for Bone Metastases in Prospective Nonrandomized Studies: A Systematic Review Tetsuo Saito,

Regional anaesthesia to improve pain outcomes in paediatric surgical patients: a qualitative systematic review of randomized controlled trials S. Suresh,

Volume 54, Issue 1, Pages (July 2008)

Managing Cancer Pain: Basic Principles and Invasive Treatments

Maximilian Burger, Ashish M. Kamat, David McConkey

How to Treat a Patient with T1 High-grade Disease and No Tumour on Repeat Transurethral Resection of the Bladder? Shahrokh Shariat, Paolo Gontero, James.

Morgan Rouprêt, Per-Uno Malmstrom, Peter Black

Presentation transcript:

Performance of the Bladder EpiCheck™ Methylation Test for Patients Under Surveillance for Non–muscle-invasive Bladder Cancer: Results of a Multicenter, Prospective, Blinded Clinical Trial J. Alfred Witjes, Juan Morote, Erik B. Cornel, Georgios Gakis, F. Johannes P. van Valenberg, Fernando Lozano, Itay A. Sternberg, Ellen Willemsen, Miriam L. Hegemann, Yossi Paitan, Ilan Leibovitch European Urology Oncology Volume 1, Issue 4, Pages 307-313 (September 2018) DOI: 10.1016/j.euo.2018.06.011 Copyright © 2018 The Author(s) Terms and Conditions

Fig. 1 Flow chart for performance analysis. Cyt+ = positive cytology; Cyt− = negative cytology; Cyt eq = equivocal cytology; Cyt oth = other cytological result; Cyt NP = Cytology not performed; NP = not performed; MD = missing data. European Urology Oncology 2018 1, 307-313DOI: (10.1016/j.euo.2018.06.011) Copyright © 2018 The Author(s) Terms and Conditions

Fig. 2 Sensitivity excluding LG Ta and Specificity by risk factors and study center. BCG = bacillus Calmette-Guérin; MMC = mitomycin C; LG = low grade. European Urology Oncology 2018 1, 307-313DOI: (10.1016/j.euo.2018.06.011) Copyright © 2018 The Author(s) Terms and Conditions

Fig. 3 Receiver operating characteristic curve for Bladder EpiCheck. (A) overall and (B) non–Ta low grade. European Urology Oncology 2018 1, 307-313DOI: (10.1016/j.euo.2018.06.011) Copyright © 2018 The Author(s) Terms and Conditions

European Urology Oncology 2018 1, 307-313DOI: (10. 1016/j. euo. 2018 Copyright © 2018 The Author(s) Terms and Conditions